clinical trial · NCT06695845
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Breast CancerGastric CancerEsophageal CancerGastroesophageal CancerColorectal CancerEndometrial CancerNon-small Cell Lung CancerOvarian CancerZanidatamab
brief summary
The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ overexpression.
started
Jan 14, 2025
primary completion
Dec 31, 2026
completion
Dec 31, 2027
last updated
Jun 9, 2026
official title
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol